Molecular Partners AG (XSWX:MOLN) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG 3-Year Dividend Growth Rate?

Molecular Partners AG's Dividends per Share for the three months ended in Dec. 2023 was CHF0.00.

The historical rank and industry rank for Molecular Partners AG's 3-Year Dividend Growth Rate or its related term are showing as below:

XSWX:MOLN's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Molecular Partners AG's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Molecular Partners AG's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Molecular Partners AG's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Molecular Partners AG's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's 3-Year Dividend Growth Rate falls into.

Molecular Partners AG 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Molecular Partners AG (XSWX:MOLN) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Molecular Partners AG's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.47
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG 3-Year Dividend Growth Rate Related Terms>

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.